TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration with Chugai Pharmaceutical Co., Ltd., has conducted an experiment using AI to predict drug combinations that can possibly enhance the effectiveness of certain cancer treatments. As a result, the time required to produce predictions may potentially be reduced by approximately 50% when compared to Chugai’s conventional methods.

Drug combination therapy, in which two or more drugs are used in combination, is a promising option in the treatment of cancer. This therapy is expected to have a higher therapeutic effect than when single agents are administered. However, the prediction of drug combinations has conventionally required time-consuming manual research and analysis of information related to diseases, mechanisms of action (*1), and indications (*2) based on vast amounts of publications and clinical trial data.

To resolve this, NEC built a system that predicts drug combinations by using in-house developed graph-based AI technology that leverages the vast amount of biochemical information and clinical trial data that is available from the AACT (*3) and ChEMBL (*4) databases. By providing the system with the name of a target drug to be administered for a cancer treatment, it can quickly suggest candidate combinations to increase the efficacy of the target drug. The system also assists in understanding and validating prediction results by providing rationales about why certain combinations are selected.

In this experiment, information on approximately 400 combinations of cancer drugs was randomly extracted from the AACT. By using this information, NEC evaluated whether candidate drugs had the potential for clinical application and if they would enhance the effectiveness of a cancer treatment when administered with other drugs. As a result, NEC confirmed that the system can potentially reduce the time required to predict drug combinations by approximately 50%. NEC also confirmed that the drug combinations suggested by the system were accurate enough for possible use and that the basis for the predictions were highly convincing.

These results show that the drug prediction system has the potential to help researchers to quickly and efficiently identify effective drug combination candidates for certain cancers.

NEC is leveraging more than 60 years of knowledge, experience and data from the healthcare and life science fields to improve the quality of medical care and enhance the health of individuals.

Going forward, NEC will continue to promote the development of drug combination therapies and contribute to the expansion of treatment options for patients by providing solutions based on proprietary AI technology.

(*1)Mechanisms of action: The specific biochemical interactions that allow a drug to exert its effects.
(*2)Indication: A disease or group of diseases for which a drug is limited and permitted
(*3)About the AACT databasehttps://aact.ctti-clinicaltrials.org/
(*4)About the ChEMBL databasehttps://www.ebi.ac.uk/chembl/

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.

Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.